NASDAQ · CTNM
Healthcare · Biotechnology
$9.69
Up+$0.10 (+1.03%)
Updated Nov 4, 2026, 10:49 PM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CTNM
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
CTNM closed at $9.69 after 21 trading sessions, down 23.40% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $9.57 | $9.94 | $9.54 | $9.69 | 526.34K |
| Nov 2, 2026 | $9.46 | $9.64 | $9.13 | $9.56 | 369.01K |
| Oct 30, 2026 | $9.14 | $9.58 | $8.93 | $9.39 | 458.62K |
| Oct 29, 2026 | $9.13 | $9.865 | $9.13 | $9.33 | 566.92K |
| Oct 28, 2026 | $8.92 | $9.34 | $8.59 | $9.15 | 570.48K |
| Oct 27, 2026 | $8.18 | $9.12 | $8.02 | $8.99 | 643.75K |
| Oct 26, 2026 | $8.25 | $8.59 | $8.02 | $8.14 | 402.68K |
| Oct 23, 2026 | $8.24 | $8.43 | $8.01 | $8.31 | 428.77K |
| Oct 22, 2026 | $8.32 | $8.7499 | $8.12 | $8.395 | 498.75K |
| Oct 21, 2026 | $8.49 | $8.79 | $8.15 | $8.35 | 1.12M |
| Oct 20, 2026 | $7.38 | $8.70 | $7.145 | $8.46 | 2.2M |
| Oct 19, 2026 | $7.01 | $7.45 | $6.725 | $7.44 | 1.8M |
| Oct 16, 2026 | $7.87 | $7.87 | $6.95 | $7.08 | 1.11M |
| Oct 15, 2026 | $8.25 | $8.56 | $7.72 | $7.90 | 1.02M |
| Oct 14, 2026 | $8.21 | $8.7955 | $7.96 | $8.14 | 1.01M |
| Oct 13, 2026 | $8.56 | $8.94 | $8.095 | $8.42 | 2.65M |
| Oct 12, 2026 | $9.90 | $11.54 | $8.425 | $8.565 | 8.47M |
| Oct 9, 2026 | $13.17 | $13.855 | $12.94 | $13.38 | 885.59K |
| Oct 8, 2026 | $12.55 | $13.29 | $12.39 | $13.18 | 1.18M |
| Oct 7, 2026 | $12.42 | $13.01 | $12.31 | $12.73 | 707.73K |
| Oct 6, 2026 | $12.88 | $12.88 | $12.17 | $12.65 | 761.92K |
The latest Smart Investors Daily articles mentioning CTNM.
Company
Market Activity
Research & News
CTNM research
Company profile and research snapshot.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 15, 2026 | Jones Trading | Buy | — |
| Oct 14, 2026 | Baird | Neutral | — |
| Sep 28, 2026 | Morgan Stanley | Equal-Weight | — |
| Sep 15, 2026 | Jones Trading | Buy | — |
| Sep 15, 2026 | Baird | Outperform | — |
No generated briefing is available yet.
Benzinga · Oct 15, 2026
Jones Trading analyst Debanjana Chatterjee maintains Contineum Therapeutics (NASDAQ:CTNM) with a Buy and raises the price target from $24 to $30.
Benzinga · Oct 14, 2026
Baird analyst Joel Beatty downgrades Contineum Therapeutics (NASDAQ:CTNM) from Outperform to Neutral and lowers the price target from $19 to $14.
SeekingAlpha · Oct 13, 2026
Johnson & Johnson is downgraded to a Hold, citing mixed fundamentals and regulatory headwinds. Read more on JNJ stock here.
Yahoo · Oct 12, 2026
Bristol Myers Squibb scored two Phase 3 wins on Monday in lung disease and cancer. The stock fell, however.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CTNM.
